» Articles » PMID: 37183259

Therapeutic Roles of Thiazides and Loop Diuretics in Blood Pressure Control and Renal Protection Against Chronic Kidney Disease

Overview
Journal Clin Hypertens
Publisher Biomed Central
Date 2023 May 14
PMID 37183259
Authors
Affiliations
Soon will be listed here.
Abstract

Fluid overload secondary to loss of functional nephron mass can elevate blood pressure, which is characteristic of hypertension shown in chronic kidney disease (CKD). Therefore, it is logical to use diuretics at appropriate dose to lower blood pressure in patients with CKD and hypertension. Despite the theoretical background on the use of diuretics in CKD, there have been no definitive data on the effectiveness or safety of diuretics as first-line therapy for the management of hypertension in patients with CKD. Results from some clinical trials have demonstrated that diuretics would not lower blood pressure. They could even worsen electrolyte imbalance and kidney function when they are administered in patients with CKD. Major clinical practice guidelines on management of blood pressure or CKD have stated that evidence for benefits of thiazide diuretics is not conclusive yet in patients with advanced CKD, although loop diuretics are often effective for volume control at lower glomerular filtration rate. Recently, evidence for diuretics as effective blood pressure lowering agents in patients with advanced CKD is increasing. Renoprotective effect of thiazide or loop diuretics might represent a consequence of their influence on blood pressure or their ability to potentiate the effect of renin-angiotensin system blockade by making intraglomerular pressure more renin-angiotensin system-dependent, although their direct benefit on renal function remains controversial. This review summarizes recent data on the possible role of diuretics in lowering blood pressure, slowing the progression of kidney disease, and reducing cardiovascular risk in CKD patients.

Citing Articles

Magnitude of multiple drug use and determinants of vulnerability among chronic kidney disease inpatients in Ethiopia: a multi-center study.

Zeleke T, Abebe R, Wondm S, Tegegne B BMC Nephrol. 2024; 25(1):332.

PMID: 39375593 PMC: 11460044. DOI: 10.1186/s12882-024-03773-x.


Risk of CKD among patients with DM taking diuretics or SGLT2i: a retrospective cohort study in Taiwan.

Lin H, Shih P, Tsai S, Chuang W, Hsieh T, Lin H BMC Pharmacol Toxicol. 2024; 25(1):24.

PMID: 38443996 PMC: 10913410. DOI: 10.1186/s40360-024-00745-7.


Therapeutical Approach to Arterial Hypertension - Current State of the Art.

Radosavljevic M, Vucevic D, Samardzic J, Radenkovic M, Radosavljevic T Curr Med Chem. 2024; 31(29):4602-4620.

PMID: 38303535 DOI: 10.2174/0109298673274823231220063652.


An Update on Drug-Nutrient Interactions and Dental Decay in Older Adults.

Bell V, Rodrigues A, Antoniadou M, Peponis M, Varzakas T, Fernandes T Nutrients. 2023; 15(23).

PMID: 38068758 PMC: 10708094. DOI: 10.3390/nu15234900.


Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.

Koh E, Kim G, Chung S Endocrinol Metab (Seoul). 2023; 38(4):359-372.

PMID: 37482684 PMC: 10475968. DOI: 10.3803/EnM.2023.1764.

References
1.
James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

2.
Hayashi S, Seeberger A, Lind B, Gunnes S, Alvestrand A, do Nascimento M . Acute effects of low and high intravenous doses of furosemide on myocardial function in anuric haemodialysis patients: a tissue Doppler study. Nephrol Dial Transplant. 2007; 23(4):1355-61. DOI: 10.1093/ndt/gfm805. View

3.
GUYTON A . Blood pressure control--special role of the kidneys and body fluids. Science. 1991; 252(5014):1813-6. DOI: 10.1126/science.2063193. View

4.
Kwakernaak A, Krikken J, Binnenmars S, Visser F, Hemmelder M, Woittiez A . Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2014; 2(5):385-95. DOI: 10.1016/S2213-8587(14)70030-0. View

5.
Khan Y, Sarriff A, Adnan A, Khan A, Mallhi T . Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center. Clin Exp Nephrol. 2017; 21(6):1011-1023. DOI: 10.1007/s10157-017-1397-6. View